Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Go back to Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study| Gilead Sciences (NASDAQ: GILD) | Delayed: 130.21 -1.07 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $131.28 | 52 Week High | $108.63 | |||
| Open | $130.23 | 52 Week Low | $71.39 | |||
| Day High | $130.89 | P/E | 71.94 | |||
| Day Low | $128.76 | EPS | $1.81 | |||
| Volume | 6,531,643 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 130.20 +0.41 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $129.79 | 52 Week High | $65.46 | |||
| Open | $128.92 | 52 Week Low | $47.97 | |||
| Day High | $131.04 | P/E | 88.57 | |||
| Day Low | $128.14 | EPS | $1.47 | |||
| Volume | 7,738,336 | |||||
